Bar
Bar

Inspiring clinicians and investigators since 1950

We are at an unprecedented nexus in medical research with the rise of distinct therapeutic platforms that promise definitive therapies for previously chronic or incurable diseases. Because of its accessibility, the skin has traditionally provided mechanistic insights that underpin the platform, and a proving ground for the early human studies.

At the 72nd annual Montagna Symposium, participants will learn about the basic science underpinnings for exciting emerging small molecule, antibody, RNA, and cell and gene therapeutics, early successes of the platform and their targets, and gaps in knowledge where additional investigation will lead to improved and long-lasting definitive therapies.

Program Chair
Anthony Oro, MD, PhD

Co-Organizers
Masa Amagai, MD, PhD
Aimee Payne, MD, PhD

Symposium Co-directors
Tamia Harris-Tryon, MD, PhD
Sancy Leachman, MD, PhD
Dennis Roop, PhD

Symposium Director Emerita
Molly Kulesz-Martin, PhD

Symposium Objectives (subject to change):

  1. Further the attendees’ understanding of the mechanistic basis of tissue regeneration therapies and the current patient responses.
  2. Elucidate the mechanistic basis of precision immune therapies and the current patient responses
  3. Explore the mechanistic basis of novel immunomodulatory therapies and the current patient responses.
  4. Gain a better understanding of the mechanistic basis of RNA medicines and the current patient responses
  5. Explore the mechanistic basis of novel cancer therapeutics and the current patient responses, generating dialogue to bridge these gaps and inspire research directions.
  6. Facilitate networking activities as a catalyst for future collaborative research endeavors and relationships

Sessions:

  • Session 1: Novel Approaches and Targets for Precision Immune Cell Therapies
  • Session 2: Tissue Regeneration Therapeutic Approaches
  • Session 3: Novel Immuomodulatory Approaches to Cutaneous Disease
  • Session 4: RNA Medicines for Cutaneous Diseases
  • Session 5: Novel Cancer Therapeutics for Cutaneous Oncology

Target Audiences:

Oncologists, Immunologists, Dermatologists, Biologists, Geneticists, Biomedical Engineers. MDs (Including HCPs), PhDs, MD/PhDs, Fellows, Dermatology Residents, Post Doctoral Researchers, Students.

The breakdown of attendees with a PhD and MD shows that clinicians and researchers attend this conference in comparable numbers, meeting our goal to bridge the gap between research and clinical care and create a multi-disciplinary event.
  • Past attendees have provided the following feedback:
    • 95% of respondents had met researchers or clinicians with whom they might consult or collaborate.
    • 92% of surveyed attendees said they learned new information and strategies that they can apply to work or practice.
    • 98% of attendees indicated they had learned novel ideas/strategies to treat skin conditions.
    • 97% of survey respondents rated the contribution to their research knowledge as excellent or good.
    • 30% of survey respondents indicated they were practicing MDs/DOs in the medical field.